Upsher-Smith buys UK's Proximagen for £223m plus CVR
This article was originally published in Scrip
Upsher-Smith Laboratories of the US is to buy the UK firm Proximagen for £223 million plus a potential £134 million through contingent value rights (CVRs) based on the success of two drugs in its pipeline.
You may also be interested in...
The hope artificial intelligence can revolutionize current drug discovery methods will be tested in a new collaboration between UK-based BenevolentAI and the medical research charity MRC Technology.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.